Array BioPharma hires vp of clinical sciences

Karsten Witt will lead clinical science and drug safety activities

Karsten Witt has joined Array BioPharma of Boulder, Colorado, US as vp of clinical sciences. With 26 years of experience in medicine and 19 years working in the pharmaceutical industry, Dr Witt will lead clinical science and drug safety activities for Array's pipeline of small molecule drugs to treat cancer and inflammatory diseases.

‘Karsten brings valuable experience to Array to help us move our proprietary pipeline to the next level,’ said chief executive Robert Conway. ‘His expertise in advancing therapeutics for cancer and inflammation, including the registration of Tarceva (erlotinib), will enable him to make immediate contributions to our proprietary programmes as we move into pivotal studies.’

From 2002 until he joined Array, Witt served as senior vp, Pharmaceutical Operations at OSI Pharmaceuticals, where he was involved in the development of small-molecule targeted oncology therapies, including the EGFR inhibitor Tarceva. Witt was also a member of OSI's Executive Management Committee starting in 2008.

From 1998 to 2001, he was senior director of Clinical Research & Drug Safety at NeXstar Pharmaceuticals, and continued in that position after NeXstar's acquisition by Gilead Sciences.

Witt worked at Synergen, where he assisted in setting up the company's European headquarters; in 1995, after Amgen purchased Synergen, he continued as a clinical scientist, working primarily on inflammation programmes, including the IL-1ra programme, which subsequently produced Kineret (anakinra).

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now